SEEKAnti-CD19/BCMA CAR-NK Cells for B Cell Mediated Autoimmune Disease

This study focuses on evaluating a new treatment using CAR-NK cells for people with certain autoimmune diseases, specifically systemic lupus erythematosus (SLE) and multi-drug resistant nephrotic syndrome (MDR-SRNS). These conditions occur when the immune system mistakenly attacks healthy tissues, leading to serious health problems, including organ damage. Current treatments are not effective for everyone, especially children with SLE who often experience more severe symptoms. There's a significant need for new treatments, as many patients struggle to achieve remission. CAR-NK cell therapy, a method that uses modified immune cells to target disease-related cells, may offer a safer, more affordable, and effective alternative to existing therapies. Participants in this study will receive CAR-NK cells, which are specially engineered immune cells designed to target and destroy harmful cells in the body, through an injection. The study aims to assess the safety and effectiveness of this treatment approach. Researchers will closely monitor participants for any changes in their condition and check for potential side effects. This early phase study hopes to provide insight into whether CAR-NK cell therapy can be a viable treatment option for these challenging autoimmune diseases, potentially improving outcomes for patients who have not responded well to other treatments.